Don't Expect Upside Until AMGN Data - Stifel Maintains Mirati Therapeutics (MRTX) at Buy
Tweet Send to a Friend
Stifel analyst Ben Burnett reiterated a Buy rating on Mirati Therapeutics (NASDAQ: MRTX) following the company's latest data readout. The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
